Economic evaluation of valsartan in patients with chronic heart failure: Results from Val-HeFT adapted to The Netherlands

Journal of Medical Economics

Volumn 9, Issue 121-131, 2006, Pages 121-131

  Boersma, Cornelis ^a,e   Radeva, Jasmina I ^b   Koopmanschap, Marc A ^c   Voors, Adriaan A ^d   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Antonius Deusinglaan 1   (Netherlands)

Author keywords

Economic evaluation; The Netherlands; Val HeFT; Valsartan

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; NITRIC ACID DERIVATIVE; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL RESEARCH; DRUG COST; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846157391     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: 10.3111/200609121131     Document Type: Article

References (25)

1. Jaarsma T, Haaijer-Ruskamp FM, Sturm H et al. Management of heart failure in The Netherlands. European Journal of Heart Failure 2005; 7: 371-375.
2. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. European Heart Journal 1999; 20: 447-455.
3. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596-602.
4. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart 2002; 87: 75-76.
5. Mosterd A, Hoes AW. Reducing hospitalizations for heart failure. European Heart Journal 2002; 23: 842-845.
6. McMurray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. European Journal of Heart Failure 2005; 7: 710-721.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001; 345: 1667-1675.
8. Maggioni AP, Anand I, Gottlieb SO et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 2002; 40: 1414-1421.
9. Reed SD, Friedman JY, Velazquez EJ et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 2004; 148: 122-128.
10. Gold MR, Siegel JE, Russel LB et al. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
11. Reed SD, Friedman JY, Gnanasakthy A et al. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. International Journal of Technology Assessment in Health Care 2003; 19: 396-406.
12. Reed SD, Anstrom KJ, Bakhai A et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. American Heart Journal 2005; 149: 434-443.
13. Health Care Insurance Board. Dutch guidelines for pharmacoeconomic research. Diemen, The Netherlands: Health Care Insurance Board, 2004.
14. Den Haag: Z-index. Z-index. G-standard 1999 [CD-ROM]. 1999.
15. Drugs Facts and Comparisons 2001. St Louis, MO: Facts and Comparisons Publishing Group, 2001.
16. Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Annals of Internal Medicine 1997; 127: 752-756.
17. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. Journal of Cardiac Failure 2003; 9: 164-171.
18. Majani G, Giardini A, Opasich C et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. Journal of Cardiac Failure 2005; 11: 253-259.
19. Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clinical Therapeutics 2005; 27: 951-959.
20. Bart BA, Ertl G, Held P et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. European Heart Journal 1999; 20: 1182-1190.
21. College voor zorgverzekeringen. CFH-rapport 05/25. AT1-antagonisten, herboordeling. Diemen, The Netherlands: College voor zorgverzekeringen, 2005 [in Dutch].
22. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal 2001; 22: 1527-1560.
23. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal 2005; 26: 1115-1140.
24. Skrepnek GH, Abarca J, Malone DC et al. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. Annals of Pharmacotherapy 2005; 39: 1785-1791.
25. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England Journal of Medicine 2003; 349(20): 1893-1906.